← Back

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Price · split & dividend adjusted
News & notes moving MLTX
MLTX▼

MoonLake Immunotherapeutics CFO Matthias Bodenstedt sells 39,120 shares for approximately $862,000

MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt sold 39,120 Class A ordinary shares in an open-market transaction on June 22, valued at approximately $862,000 based on a reported price of $22.04 per share. The sale represented 3.4% of his direct holdings, leaving him with 1,115,435 shares directly held after the transaction. The transaction was executed under a pre-arranged 10b5-1 trading plan, similar to recent sales by CEO Jorge Santos da Silva, and does not involve any indirect holdings or derivative instruments. MoonLake Immunotherapeutics is a clinical-stage biotechnology company with a market capitalization of $1.5 billion and a trailing twelve-month net loss of $259.5 million, and its stock remains highly sensitive to clinical development news.
MLTX ▼
The Motley Fool·54dRead more ▾
Biotech & Genomic Medicine▲2

MoonLake Immunotherapeutics Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa

MoonLake Immunotherapeutics received a reiterated Buy rating and $70 price target from Clear Street, with the firm highlighting the competitive profile of sonelokimab in hidradenitis suppurativa and a significant commercial opportunity. The Biologics License Application submission remains expected by September 30, and management continues to view the possibility of priority review. Separately, the company priced an underwritten public offering of 9 million Class A ordinary shares at $20.00 per share and pre-funded warrants for up to 1 million additional shares at $19.9999 per warrant, expected to generate approximately $200 million in gross proceeds before fees and expenses. Underwriters have a 30-day option to purchase an additional 1.5 million Class A ordinary shares. Proceeds will support research, development, pre-commercialization, and commercialization activities for sonelokimab, if approved, and general corporate purposes.
MLTX ▲
Biotech & Genomic Medicine
Insider Monkey·57dRead more ▾
MLTX▼8

MoonLake Immunotherapeutics shares fall 6% after upsized $200 million share offering

MoonLake Immunotherapeutics shares fell nearly 6% on Wednesday after the company priced an upsized secondary share offering. The clinical-stage biotech is floating 9 million class A ordinary shares at $20 each, with certain investors also able to purchase pre-funded warrants for up to 1 million additional shares. Underwriters have a 30-day option to buy up to 1.5 million more shares. Gross proceeds are expected to be between $180 million and $200 million, up from a prior target of at least $150 million. The funds will support research, pre-commercialization, and commercialization of its lead drug candidate sonelokimab, which is in late-stage development for multiple autoimmune indications.
MLTX ▼
The Motley Fool·63dRead more ▾
MLTX▼

MoonLake, Best Buy, and Domino's shares fall after hours on offering and executive exits

MoonLake Immunotherapeutics, Best Buy, and Domino's Pizza all declined in after-hours trading Monday following separate announcements. MoonLake Immunotherapeutics slipped 3.3% after unveiling a $150 million public offering of Class A ordinary shares and pre-funded warrants. Best Buy fell about 3% after disclosing that CFO Matt Bilunas will step down on July 31, ending a seven-year tenure in the role. Domino's Pizza dropped more than 2% after CEO Russell Weiner notified the board of his intention to retire effective September 30, 2026, signaling an upcoming leadership transition.
BBY ▼DPZ ▼MLTX ▼
Seeking Alpha·65dRead more ▾
Biotech & Genomic Medicine▲4impact 4

MoonLake Soars on Positive 52-Week Sonelokimab Data in Hidradenitis Suppurativa

MoonLake Immunotherapeutics announced positive 52-week results from its Phase 3 VELA-1 and VELA-2 trials of sonelokimab in moderate-to-severe hidradenitis suppurativa, sending shares up 10.26% to $21.18 in overnight trading. Across both trials, 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100 at week 52, with 26.0% reaching an IHS4-100 response indicating inflammatory remission. The company said the safety profile remained consistent with no new signals. A Biologics License Application submission is expected by the end of September 2026, with FDA filing acceptance anticipated around November 2026.
MLTX ▲
Biotech & Genomic Medicine ▲
RTTNews·66dRead more ▾
© 2026 MarketDXAsset